Western immunoblotting and enzymatic activity analysis of cathepsin D in human breast cancer cell lines of different invasive potential. Regulation by 17β-estradiol, tamoxifen and ICI 182,780

Clinical and Experimental Metastasis

Volumn 15, Issue 4, 1997, Pages 349-360

  Couissi, Driss ^a   Dubois, Vincent ^a   Remacle, Claude ^a   Schonne, Edgard ^a   Trouet, André ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Antiestrogens; Breast cancer; Cathepsin D; Estrogen; Invasive potential

Indexed keywords

ANTIESTROGEN; CATHEPSIN D; ESTRADIOL; FULVESTRANT; TAMOXIFEN;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; METASTASIS POTENTIAL; TUMOR CELL LINE;

ACIDS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BREAST NEOPLASMS; CATHEPSIN D; CULTURE MEDIA, SERUM-FREE; ENZYME ACTIVATION; ENZYME PRECURSORS; ESTRADIOL; ESTROGEN ANTAGONISTS; HUMANS; IMMUNOBLOTTING; NEOPLASM INVASIVENESS; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 0030850908     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018489819092     Document Type: Article

References (36)

1. Pujol P, Maudelonde T, Daures JP, et al. 1993, Prospective study of the prognostic value of cathepsin D levels in breast cancer cytosol. Cancer, 71, 2006-12.
2. Spyratos F, Maudelonde T, Brouillet JP, et al. 1989, Cathepsin D: an important marker predicting metastasis in primary breast cancer. Lancet, 334, 1115-18.
3. Rochefort H, 1992, Cathepsin D in breast cancer: a tissue marker associated with metastasis. Eur J Cancer, 28A, 1780-3.
4. Leto G, Gebbia N, Rausa L and Tumminello FM, 1992, Cathepsin D in the malignant progression of neoplastic disease (review). Anticancer Res, 12, 235-40.
5. Mathieu M, Vignon F, Capony F and Rochefort H, 1991, Estradiol down-regulates the mannose 6-phosphate/insulin-like growth factor-II receptor gene and induces cathepsin D in breast cancer cells: a receptor saturation mechanism to increase the secretion of lysosomal proenzymes. Mol Endocr, 5, 815-22.
6. Van Beek WP, Smets LA and Emmelot P, 1973, Increased sialic acid density in surface glycoprotein of transformed and malignant cells: a general phenomenon? Cancer Res, 33, 2913-22.
7. Baron R, Neff L, Louvard D and Courtoy PJ, 1985, Cell-mediated extracellular acidification and bone resorption: evidence for a low pH in resorbing lacunæ and localization of a 100-KD lysosomal membrane protein at the osteoclast ruffled border. J Cell Biol, 101, 2210-22.
8. Dubois V, Couissi D, Schonne E, Schneider Y-J, Remacle C and Trouet A, 1993, Estrogen and insulin modulation of intracellular insulin-like growth factor binding proteins in human breast cancer cells: possible involvement in lysosomal hydrolases oversecretion. Biochem Biophys Res Commun, 192, 295-301.
9. Rochefort H, Capony F and Garcia M, 1990, Cathepsin D: a protease involved in breast cancer metastasis. Cancer Metastasis Rev, 9, 321-31.
10. Bracke M, Van Larebeke NA, Vyncke BM and Mareel MM, 1991, Retinoid acid modulates both invasion and plasma membrane ruffling of MCF-7 human mammary carcinoma cells in vitro. Br J Cancer, 63, 867-72.
11. Thompson EW, Lippman ME and Dickson RB, 1991, Regulation of basement membrane invasiveness in human breast cancer model systems. Mol Cell Endocr, 82, C203-C208.
12. Brünner N, Boysen B, Romer J and Spang-Thomsen M, 1993, The nude mouse as an in vivo model for human breast cancer invasion and metastasis. Breast Cancer Res Treat, 24, 257-64.
13. r 52,000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res, 49, 6008-14.
14. Tandon AK, Clark GM, Chamness GC, Chirgwin JM and McGuire WL, 1990, Cathepsin D and prognosis in breast cancer. N Engl J Med, 322, 297-302.
15. Namer M, Ramaioli A, Fontana X, et al. 1991, Prognostic value of total cathepsin D in breast tumors. A possible role in selection of chemoresistant patients. Breast Cancer Res Treat, 19, 85-93.
16. Russell WC, Newman C and Williamson DH, 1975, A simple cytochemical technique for demonstration of DNA in cells infected with mycoplasma and viruses. Nature, 253, 461-2.
17. Kapuscinski J and Skoczylas B, 1977, Simple and rapid fluorimetric method for DNA microassay. Anal Biochem, 83, 252-7.
18. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ, 1951, Protein measurement with the Folin phenol reagent. J Biol Chem, 193, 265-75.
19. Orlowski M, Orlowski R, Chang JC, Wilk E and Lesser M, 1984, A sensitive procedure for determination of cathepsin D: activity in alveolar and peritoneal macrophages. Mol Cell Biochem, 64, 155-64.
20. 4. Nature, 227, 680-5.
21. Plaxton WC and Moorhead GBG, 1989, Peptide mapping by CNBr fragmentation using a sodium dodecyl sulfate-polyacrylamide minigel system. Anal Biochem, 178, 391-3.
22. Schultz DC, Bazel S, Wright LM, et al. 1994, Western blotting and enzymatic activity analysis of cathepsin D in breast tissue and sera of patients with breast cancer and benign breast disease and of normal controls. Cancer Res, 54, 48-54.
23. Capony F, Braulke T, Rougeot C, Roux S, Montcourrier P and Rochefort H, 1994, Specific mannose-6-phosphate receptor-independent sorting of procathepsin D in breast cancer cells. Exp Cell Res, 215, 154-63.
24. Johnson MD, Torri JA, Lippman ME and Dickson RB, 1993, The role of cathepsin D in the invasiveness of human breast cancer cells. Cancer Res, 53, 873-7.
25. Liaudet E, Garcia M and Rochefort H, 1994, Cathepsin D maturation and its stimulatory effect on metastasis are prevented by addition of KDEL retention signal. Oncogene, 9, 1145-54.
26. Wakeling AE, 1993, The future of new pure antiestrogens in breast cancer. Breast Cancer Res Treat, 25, 1-9.
27. Brünner N, Frandsen TL, Holsthansen C, et al. 1993, MCF7/LCC2 - a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Res, 53, 3229-32.
28. Coopman P, Garcia M, Brünner N, Derocq D, Clarke R and Rochefort H, 1994, Anti-proliferative and antiestrogenic effects of ICI 164,384 and ICI 182,780 in 4-OH-tamoxifen-resistant human breast-cancer cells. Int J Cancer, 56, 295-300.
29. DeFriend DJ, Howell A, Nicholson RI, et al. 1994, Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res, 54, 408-14.
30. Maudelonde T, Escot C, Pujol P, et al. 1994, In vivo stimulation by tamoxifen of cathepsin D RNA level in breast cancer. Eur J Cancer, 30A, 2049-53.
31. Dubois V, Couissi D, Schonne E, Remacle C and Trouet A, 1995, Intracellular levels and secretion of insulin-like growth factor binding proteins in MCF-7/6, MCF-7/AZ and MDA-MB-231 breast cancer cells. Differential modulation by estrogens in serum-free medium. Eur J Biochem, 232, 47-53.
32. Pfeffer U, Fecarotta E and Vidali G, 1995, Coexpression of multiple estrogen receptor variant messenger RNAs in normal and neoplastic breast tissues and in MCF-7 cells. Cancer Res, 55, 2158-65.
33. Mahfoudi A, Roulet E, Dauvois S, Parker MG and Wahli W, 1995, Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists. Proc Natl Acad Sci, USA, 92, 4206-10.
34. Larsen LB, Boisen A and Petersen TE, 1993, Procathepsin-D cannot autoactivate to cathepsin-D at acid pH. FEBS Lett, 319, 54-8.
35. Conner GE and Richo G, 1992, Isolation and characterization of a stable activation intermediate of the lysosomal apartyl protease cathepsin D. Biochemistry 31, 1142-47.
36. r 52,000 cathepsin D secreted by breast cancer cells. Cancer Res, 48, 3688-92.